These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29164377)

  • 1. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).
    Barton DL; Shuster LT; Dockter T; Atherton PJ; Thielen J; Birrell SN; Sood R; Griffin P; Terstriep SA; Mattar B; Lafky JM; Loprinzi CL
    Support Care Cancer; 2018 Apr; 26(4):1335-1343. PubMed ID: 29164377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance).
    Barton DL; Sloan JA; Shuster LT; Gill P; Griffin P; Flynn K; Terstriep SA; Rana FN; Dockter T; Atherton PJ; Tsai M; Sturtz K; Lafky JM; Riepl M; Thielen J; Loprinzi CL
    Support Care Cancer; 2018 Feb; 26(2):643-650. PubMed ID: 28921241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C; Labrie F; Archer DF; Ke Y; Gonthier R; Simard JN; Lavoie L; Vaillancourt M; Montesino M; Balser J; Moyneur É;
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA.
    Ke Y; Gonthier R; Simard JN; Archer D; Lavoie L; Martel C; Vaillancourt M; Labrie F
    Horm Mol Biol Clin Investig; 2015 Dec; 24(3):117-29. PubMed ID: 26509785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Bérubé R; Bélanger P; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):897-906. PubMed ID: 19436226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.
    Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
    J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):178-94. PubMed ID: 18598765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
    Ke Y; Labrie F; Gonthier R; Simard JN; Bergeron D; Martel C; Vaillancourt M; Montesino M; Lavoie L; Archer DF; Balser J; Moyneur E;
    J Steroid Biochem Mol Biol; 2015 Nov; 154():186-96. PubMed ID: 26291918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
    J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a 3-week dehydroepiandrosterone administration on sleep, sex steroids and multiple 24-h hormonal profiles in postmenopausal women: a pilot study.
    Caufriez A; Leproult R; L'Hermite-Balériaux M; Kerkhofs M; Copinschi G
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):716-24. PubMed ID: 23488643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
    Archer DF
    J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
    Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
    Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
    JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
    Panjari M; Davis SR
    Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
    Portman DJ; Labrie F; Archer DF; Bouchard C; Cusan L; Girard G; Ayotte N; Koltun W; Blouin F; Young D; Wade A; Martel C; Dubé R;
    Menopause; 2015 Dec; 22(12):1289-95. PubMed ID: 25968836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors.
    Kallak TK; Baumgart J; Göransson E; Nilsson K; Poromaa IS; Stavreus-Evers A
    Menopause; 2014 Apr; 21(4):383-90. PubMed ID: 24080848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer.
    Johansson H; Bonanni B; Mariette F; Cazzaniga M; Baglietto L; Guerrieri-Gonzaga A; Sandri MT; Luini A; Pelosi G; Decensi A
    Breast Cancer Res Treat; 2006 Jul; 98(2):167-72. PubMed ID: 16538534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E
    J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.